Jamaican researchers to headline global medical cannabis symposium in London
Two of Jamaica’s leading medical cannabis
researchers, Professor Henry Lowe and Professor Errol Morrison, will headline
day one of the Global Medical Cannabis Research Symposium in London on Wednesday,
September 18.
The two-day, invite-only symposium was borne out of a partnership between the UK Centre for Medicinal Cannabis (CMC) and the Jamaican Medical Cannabis Corporation (JMCC).
Both distinguished fellows will be among
other medical researchers and clinicians from around the globe and will share
their own research experience and Jamaica’s history with medicinal cannabis
with their UK peers.
Dr. Lowe, a medical cannabis pioneer and
Chief Executive Officer (CEO) of Medicanja, was asked to share key findings
from current research during a session titled: Clinical Trials for AML and
Pancreatic Cancer.
Dr. Lowe will discuss his cannabis-based
FDA-approved “orphan drug” for Acute Myeloid Leukemia. Having been so
designated in 2017, the US Orphan Drug Act provides for the granting of special
status to a drug or biological product to treat a rare disease or condition
upon the request of a sponsor.
Meanwhile, Dr. Lowe will be preceded at the
symposium by Prof. Morrison, Director General of the Jamaican National
Commission of Science and Technology.
Prof. Morrison will set the stage with “A
Short History of the Therapeutic Use of Cannabis.”
The presentation will highlight ancient
cannabis uses in China, India, Africa, up to traditional medicine and
contemporary research in Jamaica.
Other speakers include: Dr. Saoirse O’Sullivan, Science Lead, Centre for Medicinal Cannabis; Dr. Elyad Davidson, Hadassah Hebrew University, Israel; Dr. Evan Cole Lewis, Director, Neurology Centre of Toronto; and Dr. Regina Nelson, Founder of the eCS Therapy Center in Colorado, USA.
Attendees will learn about current UK and
international research projects focused on cancer, pain management, paediatric
epilepsy, AML, gastrointestinal disorders, sexual dysfunction and other
conditions. Other sessions will facilitate the exchange of experiences on
research and clinical trial best practices, and funding sources.
